(Reuters) -GSK said its vaccine for respiratory syncytial virus (RSV) showed positive preliminary results in a late-stage trial to protect adults aged 50 to 59 from the disease that causes thousands of hospitalisations and deaths annually.
The British drugmaker’s shot, called Arexvy, met the primary goal in the Phase-III trial of eliciting an immune response in adults of the reported age group who are at an increased risk of catching the virus due to certain underlying medical conditions, the company said on Wednesday.
RSV typically causes cold-like symptoms, but is a leading cause of pneumonia in toddlers and the elderly.
The shot has already been approved in the United States, Europe, Japan and other countries to protect adults aged 60 years and older.
(Reporting by Eva Mathews in Bengaluru; Editing by Sherry Jacob-Phillips)
